UPDATE 1-Third U.S. patent on Teva's MS drug Copaxone invalidated

NEW YORK, Sept 1 (Reuters) - U.S. patent officials on

Thursday invalidated a third patent for Teva Pharmaceutical

Industries' $4 billion multiple sclerosis treatment

Copaxone, saying it did not deserve legal protection, after

cancelling two other patents on the drug last week.

Read more